Adial Pharmaceuticals Changes Name to Azora Therapeutics
Bitget2026/10/28 20:03- Adial Pharmaceuticals changed its name to Azora Therapeutics, focusing on treatments for inflammatory diseases.
- Common stock is expected to begin trading on Nasdaq under ticker AZR on October 29, 2026.
- Matt Davidson was appointed president and chief executive officer to lead the new executive team.
- Lead candidate AT177, an oral, colon-targeted AhR agonist for ulcerative colitis, is expected to enter Phase 1 trials in first-half 2027.
- Current cash and cash equivalents are expected to fund operational plans into 2028.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
